Viatris Inc. Common Stock

VTRS trades at an RSI of 71.4—firmly overbought territory—yet the stock sits nowhere near its 52-week high, suggesting momentum has run ahead of price discovery. With a $17.5B market cap and negligible short interest at 3.04% of float, there's minimal squeeze potential to provide upside catalysts. The absence of a P/E ratio raises questions about profitability or valuation metrics worth scrutinizing. This overbought reading combined with the company's distance from annual highs hints at potential mean reversion risk, though the pharmaceutical sector's resilience shouldn't be dismissed outright.